[go: up one dir, main page]

AR013886A1 - Proteinas utiles para tratar la obesidad y condiciones asociadas con la obesidad; composiciones farmaceuticas formuladas con dichas proteinas;compuestos polinucleoticos de dna que codifican dichas proteinas y procedimiento para pepararlas - Google Patents

Proteinas utiles para tratar la obesidad y condiciones asociadas con la obesidad; composiciones farmaceuticas formuladas con dichas proteinas;compuestos polinucleoticos de dna que codifican dichas proteinas y procedimiento para pepararlas

Info

Publication number
AR013886A1
AR013886A1 ARP970105941A ARP970105941A AR013886A1 AR 013886 A1 AR013886 A1 AR 013886A1 AR P970105941 A ARP970105941 A AR P970105941A AR P970105941 A ARP970105941 A AR P970105941A AR 013886 A1 AR013886 A1 AR 013886A1
Authority
AR
Argentina
Prior art keywords
proteins
obesity
xaa
useful
conditions associated
Prior art date
Application number
ARP970105941A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR013886A1 publication Critical patent/AR013886A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se trata de proteínas utiles para el tratamiento de la obesidad y de trastornos relacionados con estado de obesidad. Dichas proteínas respondena la secuencia de aminoácidos ID N* 1 dada la reivindicacion 1. Proteínas utiles para tratar la obesidad o condiciones asociadas con la obesidadcaracterizadas porque tienen la secuencia de aminoácidos ID N* 1, en la que: Xaa de la posicion 22 es Asn o Ser, Xaa de la posicion 28 es Gln o estáausente, Xaa de la posicion 72 es Asn, Gln, Glu oAsp y Xaa de la posicion 73 es Val o Met; teniendo la citada proteína por lo menos una de lassiguientes sustituciones: Trp de la posicion 100 está sustituido por Glu, Asp, His, Lys o Arg, o Trp de la posicion 138 está sustituido por Glu,Asp,His, Lys o Arg; o una sal farmacéuticamente aceptable de la misma. La invencion incluye además las formulaciones farmacéuticas que incluyen dichasproteínas como agente activo para dichos tratamientos; polinucleotidos de DNA codificantes de dichas proteínas y un procedimiento para obtener las proteínasmencionadas.
ARP970105941A 1996-12-20 1997-12-17 Proteinas utiles para tratar la obesidad y condiciones asociadas con la obesidad; composiciones farmaceuticas formuladas con dichas proteinas;compuestos polinucleoticos de dna que codifican dichas proteinas y procedimiento para pepararlas AR013886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3356196P 1996-12-20 1996-12-20

Publications (1)

Publication Number Publication Date
AR013886A1 true AR013886A1 (es) 2001-01-31

Family

ID=21871119

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105941A AR013886A1 (es) 1996-12-20 1997-12-17 Proteinas utiles para tratar la obesidad y condiciones asociadas con la obesidad; composiciones farmaceuticas formuladas con dichas proteinas;compuestos polinucleoticos de dna que codifican dichas proteinas y procedimiento para pepararlas

Country Status (23)

Country Link
EP (1) EP0849276A1 (es)
JP (1) JPH10179158A (es)
KR (1) KR19980064258A (es)
CN (1) CN1194986A (es)
AR (1) AR013886A1 (es)
AU (2) AU4843297A (es)
BR (1) BR9706358A (es)
CA (1) CA2217698A1 (es)
CO (1) CO4700343A1 (es)
CZ (1) CZ407097A3 (es)
HU (1) HUP9702500A3 (es)
ID (1) ID19257A (es)
IL (1) IL122569A0 (es)
NO (1) NO975938L (es)
NZ (1) NZ329413A (es)
PE (1) PE47599A1 (es)
PL (1) PL323956A1 (es)
SG (1) SG65040A1 (es)
SV (1) SV1997000107A (es)
TR (1) TR199701666A3 (es)
WO (1) WO1998028335A1 (es)
YU (1) YU48997A (es)
ZA (1) ZA9710877B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100510614B1 (ko) 1997-04-15 2005-08-30 씨에스아이알 식욕 억제 활성을 갖는 화합물의 제조를 위한 중간체 및이의 제조 방법
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
GB9924484D0 (en) * 1999-10-15 1999-12-15 Isis Innovation Altered polypeptide aggregation
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
EP2030628B1 (en) 2006-06-01 2012-08-15 Yun Cheng A peptide for preventing or treating liver damage and its derivant and the use
US12466883B1 (en) * 2024-05-13 2025-11-11 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
EP0725079A1 (en) * 1995-01-31 1996-08-07 Eli Lilly And Company Anti-obesity proteins
AU4862396A (en) * 1995-02-06 1996-08-27 Eli Lilly And Company Human obesity gene
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU6284896A (en) * 1995-06-22 1997-01-22 Eli Lilly And Company Obesity protein intermediates and their preparation and use

Also Published As

Publication number Publication date
CA2217698A1 (en) 1998-06-20
SV1997000107A (es) 1999-01-18
ZA9710877B (en) 1999-06-03
WO1998028335A1 (en) 1998-07-02
AU4843297A (en) 1998-06-25
PL323956A1 (en) 1998-06-22
NO975938D0 (no) 1997-12-17
ID19257A (id) 1998-06-28
NZ329413A (en) 1999-10-28
CN1194986A (zh) 1998-10-07
SG65040A1 (en) 1999-05-25
CO4700343A1 (es) 1998-12-29
TR199701666A2 (xx) 1999-10-21
KR19980064258A (ko) 1998-10-07
PE47599A1 (es) 1999-05-14
JPH10179158A (ja) 1998-07-07
HUP9702500A2 (hu) 1998-07-28
NO975938L (no) 1998-06-22
YU48997A (sh) 1999-09-27
HU9702500D0 (en) 1998-03-02
IL122569A0 (en) 1998-06-15
HUP9702500A3 (en) 1999-07-28
EP0849276A1 (en) 1998-06-24
TR199701666A3 (tr) 1999-10-21
BR9706358A (pt) 1999-05-04
AU5384698A (en) 1998-07-17
CZ407097A3 (cs) 1998-07-15

Similar Documents

Publication Publication Date Title
NO330934B1 (no) Flytende farmasoytisk preparat samt anvendelse og fremstilling derav.
UY23561A1 (es) Procedimiento para la preparacion de tnf-muteinas
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
MXPA06010205A (es) Metodo y composiciones para el tratamiento de trastornos gastrointestinales.
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
BRPI0514199A (pt) método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7
DK0950096T3 (da) Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse
ATE165980T1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
NO960309L (no) Agonister og antagonister for humaninterleukin-10
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
EP0401903A3 (en) The use of vanilloids for the treatment of respiratory diseases or disorders
DK1007566T3 (da) Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
DE69634510T2 (de) Mutantes SPE-A-Toxin und dessen Verwendung
SE9801495D0 (sv) Protein formulationa
AR013886A1 (es) Proteinas utiles para tratar la obesidad y condiciones asociadas con la obesidad; composiciones farmaceuticas formuladas con dichas proteinas;compuestos polinucleoticos de dna que codifican dichas proteinas y procedimiento para pepararlas
DE69631837D1 (de) FCepsilon-PE, EIN CHIMÄRES PROTEIN FÜR DIE GEZIELTE BEHANDLUNG ALLERGISCHER REAKTIONEN, EINE METHODE FÜR DESSEN HERSTELLUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DIE DAS PROTEIN BEINHALTEN
ES549115A0 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
ES2184300T3 (es) Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.
ATE373091T1 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin